

# **Withholding and Withdrawing Life-prolonging Medical Treatment**

Guidance for decision making

**THIRD EDITION**

**British Medical Association**





# **Withholding and Withdrawing Life-prolonging Medical Treatment**

Guidance for decision making



# **Withholding and Withdrawing Life-prolonging Medical Treatment**

Guidance for decision making

**THIRD EDITION**

**British Medical Association**



© 2007 British Medical Association

Published by Blackwell Publishing

BMJ Books is an imprint of the BMJ Publishing Group Limited, used under licence

Blackwell Publishing, Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA

Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK

Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia

The right of the Author to be identified as the Author of this Work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

First published 1999

Second edition 2001

Third edition 2007

1 2007

ISBN: 978-1-4051-5957-9

Catalogue records for this title are available from the British Library and the Library of Congress

Set in 9.5/12 by Techbooks, India

Printed and bound in Singapore by COS Printers Pte Ltd

Commissioning Editor: Mary Banks

Editorial Assistant: Vicki Pittman

Development Editor: Charlie Hamlyn

Production Controller: Rachel Edwards

For further information on Blackwell Publishing, visit our website:

<http://www.blackwellpublishing.com>

The publisher's policy is to use permanent paper from mills that operate a sustainable forestry policy, and which has been manufactured from pulp processed using acid-free and elementary chlorine-free practices. Furthermore, the publisher ensures that the text paper and cover board used have met acceptable environmental accreditation standards.

Blackwell Publishing makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check that any product mentioned in this publication is used in accordance with the prescribing information prepared by the manufacturers. The author and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this book.

# Contents

Medical Ethics Committee	viii
Editorial board for the third edition	x
Acknowledgements for the third edition	xi
Introduction	xii
<b>Part 1: How to use this guidance</b>	<b>1</b>
1. Scope, purpose and structure of this guidance	1
<b>Part 2: Defining key terms and concepts</b>	<b>3</b>
2. The primary goal of medicine	3
3. Life-prolonging treatment	5
4. Capacity and incapacity	5
5. Duty of care	6
6. Quality of life	8
7. Benefit	10
8. Harm	11
9. Best interests	12
10. Futility	14
11. Basic care	15
12. Artificial nutrition and hydration	15
13. Oral nutrition and hydration	17
14. Foresight and intention	18
15. Withholding or withdrawing treatment	19
16. Conscientious objection	20
17. Resource management	21
<b>Part 3: Legal and ethical considerations that apply to all decisions to withhold or withdraw treatment</b>	<b>23</b>
18. Human Rights Act 1998	23
19. Fairness and non-discrimination	28
20. Communication	31
21. Confidentiality	32
22. Legal review	34

<b>Part 4: Medical considerations that apply to all decisions to withhold or withdraw treatment</b>	<b>36</b>
23. Medical assessment	36
24. Medical decision making	39
<b>Part 5: Decision making by adults with capacity</b>	<b>43</b>
25. The law	43
26. Communication and information	47
<b>Part 6: Decision making on behalf of adults who lack capacity</b>	<b>50</b>
England and Wales	50
27. Patients with a Lasting Power of Attorney (LPA)	50
28. Patients with an advance decision about medical treatment	52
29. Patients without a Lasting Power of Attorney or advance decision	57
30. Patients in persistent vegetative state (pvs)	61
Scotland	62
31. Patients with a welfare power of attorney or welfare guardian	62
32. Patients with an advance decision about medical treatment	64
33. Patients without a welfare power of attorney or advance decision	67
34. Patients in persistent vegetative state (pvs)	68
Northern Ireland	69
35. Patients with an advance decision about medical treatment	69
36. Patients without an advance decision about medical treatment	69
37. Patients in persistent vegetative state (pvs)	71
All UK jurisdictions	72
38. Capacity and incapacity	72
39. Communication and information	73
40. Assessing best interests	77
41. Dealing with disagreement	80
<b>Part 7: Decision making by young people with capacity</b>	<b>83</b>
42. The law in England, Wales and Northern Ireland	83
43. The law in Scotland	88
44. Assessing capacity	91
45. Communicating with young people	92
46. Dealing with disagreement	95



<b>Part 8: Decision making for children and young people who lack capacity</b>	<b>96</b>
47. The law	96
48. Duties owed to babies and children	102
49. Communicating with parents	104
50. Assessing best interests	106
51. Dealing with disagreement	108
<b>Part 9: Once a decision has been reached</b>	<b>109</b>
52. Keeping others informed	109
53. Recording and reviewing the decision	109
54. Providing support	111
55. Respecting patients' wishes after death	113
Appendix 1 Useful addresses	114
References	118
Index	123

# Medical Ethics Committee

A publication from the BMA's Medical Ethics Committee (MEC) whose membership for 2006/07 was:

Professor Parveen Kumar	President, BMA
Dr Michael Wilks*	Chairman of the Representative Body, BMA
Mr James Johnson	Chairman of Council, BMA
Dr David Pickersgill	Treasurer, BMA
Dr Anthony Calland	Chairman, Medical Ethics Committee; General Practitioner, Gwent
Dr Jonathan Brett	Junior doctor, general practice, Newcastle-upon-Tyne
Dr John Chisholm*	General Practitioner, London
Dr Peter Dangerfield	Medical Academic, Liverpool
Professor Bobbie Farsides*	Professor of Medical Law and Ethics, Brighton
Professor Ilora Finlay*	Consultant in Palliative Medicine, Cardiff
Professor Robin Gill*	Professor of Modern Theology, Canterbury
Professor Raanan Gillon*	General Practitioner; Professor of Medical Ethics, London
Dr Evan Harris*	Member of Parliament; former hospital doctor, Oxford
Professor John Harris	Sir David Alliance Professor of Bioethics, Manchester
Professor Emily Jackson*	Professor of Law, London
Dr Craig Knott	House Officer, London
Dr Surendra Kumar	General Practitioner, Widnes, Cheshire
Professor Sheila McLean*	Director of Institute of Law and Ethics, Glasgow
Professor Jonathan Montgomery	Professor of Health Care Law, Southampton
Professor Ruud ter Meulen	Professor of Ethics in Medicine, Bristol
Dr Peter Tiplady (deputy)	Retired, East Cumbria

Dr Frank Wells (deputy)	Retired, Suffolk
Dr Jan Wise	Consultant Psychiatrist, London
Dr John Jenkins	General Medical Council Observer
Ms Jane O'Brien	General Medical Council Observer
Mr Chris Chaloner	Royal College of Nursing Observer

\*Sub-group of the MEC to discuss this guidance

# **Editorial board for the third edition**

Head of Medical Ethics: Ann Sommerville  
Project Manager: Veronica English  
Written by: Veronica English  
Editorial Secretary: Patricia Fraser

Information about major developments since the publication of this guidance may be obtained from the BMA's website at: [www.bma.org.uk/ethics](http://www.bma.org.uk/ethics) or by contacting the Medical Ethics Department:

British Medical Association  
BMA House  
Tavistock Square  
London WC1H 9JP

Tel: 020 7383 6286  
Fax: 020 7383 6233  
Email: [ethics@bma.org.uk](mailto:ethics@bma.org.uk)

## **Acknowledgements for the third edition**

We would like to thank those individuals and organisations who generously gave their time to review an earlier draft of this guidance. Whilst these contributions helped to inform the BMA's views, it should not be assumed that this guidance necessarily reflects the views of all those who contributed. We would particularly like to thank Anna Batchelor, Intensive Care Society; Beverly Taylor, Office of the Official Solicitor; Charlie McLaughlan, Royal College of Anaesthetists; Chris Chaloner, Royal College of Nursing; Donald Lyons, Mental Welfare Commission Scotland; Emma Wilbraham, Department of Health; Kathleen Glancy, Scottish Executive Health Department; Mike Hinchliffe, Children and Family Court Advisory and Support Service (CAFCASS); Ranald Macdonald, NHS Scotland Central Legal Office; Resuscitation Council (UK); Sandra McDonald, Office of the Public Guardian (Scotland); Sharon Burton and Roger Worthington, General Medical Council; Toby Williamson, Department for Constitutional Affairs.

# Introduction

In medicine, decisions are made on a daily basis about the provision, withholding or withdrawing of treatments, some of which could prolong life. Treatments which might provide a therapeutic benefit are not inevitably given but are weighed according to a number of factors, such as the patient's wishes, the treatment's invasiveness, side-effects, limits of efficacy and the resources available. The Intensive Care Society has estimated that approximately 50,000 patients are admitted to intensive care units in England and Wales each year. Of these, 30% (15,000 patients) die without leaving hospital, most as a result of active treatment being withdrawn [1].

Although not uncommon, few issues in medicine are more complex and difficult than those addressed by patients, their relatives and their doctors concerning the decision to withhold or withdraw potentially life-prolonging treatment. Technological developments continually extend the range of treatment options available to prolong life when organ or system failure would naturally result in death. Cardiopulmonary resuscitation, renal dialysis, artificial nutrition, hydration and ventilation prolong life and, in some cases, allow time for recovery but these techniques cannot, in themselves, reverse a patient's disease. Patients with progressive conditions such as motor neurone disease can have their lives prolonged by the application of technology, but their underlying illness cannot be cured and deterioration in their condition is unavoidable. The condition of other patients, for example those with very severe brain damage, may remain stable for many years if life-prolonging treatment is provided but they may have no hope of recovering more than very minimal levels of awareness of their surroundings. They may lack the ability to interact with others or capacity for self-awareness or self-directed action. In such severely damaged patients, interventions to prolong life by artificial means may fail to provide sufficient benefit to justify the burdens of intervention (see Section 9) and the proper course of action may be to withhold or withdraw further treatment.

Most people accept that treatment should not be prolonged indefinitely when it has ceased to provide a benefit for the patient. But patients and their families, doctors and other members of the clinical team and society as a whole need reassurance that individual decisions are carefully thought through, based on the best quality information available and follow a widely

agreed procedure. Decisions need to be made on an individual basis, assessing the particular circumstances, wishes and values of the patient to ensure that treatment is neither withdrawn too quickly nor unnecessarily prolonged. It is essential that there are clear, robust and transparent procedures for making these decisions. The BMA is very pleased to note that, over recent years, comprehensive guidance has been developed outlining the criteria and steps to be followed in making these decisions, particularly where difficult assessments are required about the best interests of incapacitated patients. In addition to the BMA's guidance, first published in 1999, there is now also detailed advice from the General Medical Council [2] and from the Royal College of Paediatrics and Child Health [3]. There is also statutory guidance for those providing treatment for adults who lack capacity, in the form of Codes of Practice under the Adults with Incapacity (Scotland) Act 2000 [4] and the Mental Capacity Act 2005 [5]. Nevertheless, there is only benefit in having guidance if it is available to, and used by, those responsible for making these decisions. Occasional media reporting has served to remind us that best practice is not yet universal and that we all have a responsibility to ensure that good communication and decision-making procedures are followed in all cases. In this document, the BMA seeks to provide a coherent and comprehensive set of principles which apply to all decisions to withhold or withdraw life-prolonging treatment. It is hoped that this general guidance will stimulate the development of accessible local policies and guidelines as part of a wider network of safeguards for doctors and patients.

The need for guidance in this area became clear from a wide-ranging consultation exercise undertaken by the BMA in 1998. This led to the first edition of this guidance being published in 1999. A second edition was published in 2001 to incorporate specific guidance on the impact of the Human Rights Act. This third edition includes subsequent developments in legislation – specifically the Mental Capacity Act (which at the time of writing was due to come into force in 2007) – and the common law. Although these changes have clarified some aspects of the law, some legal uncertainties remain and judicial review will still be required in particular cases. Part of the aim of this guidance is to identify the type of cases where decisions may be made by the patient, the health care team and/or those close to the patient and those where a declaration from a court is required. This guidance does not set out to give definitive legal advice but to explain the legal and ethical principles that underpin decision making in this area and to help health professionals to recognise when further advice is needed. Of course, the law will not remain static and information about any major developments following publication will be posted on the BMA's website at [www.bma.org.uk/ethics](http://www.bma.org.uk/ethics).